The Wacker Biotechnology Center is in Munich, where the company has been conducting fundamental research for over a century.

The acquisition of Avivia aligns with Ofichem’s broader merger and acquisition agenda and ongoing investment strategy.

This could lead to the development of precision allergy treatments that are fast acting, needle free, and tailored to individual allergen sensitivities.

A newly developed generative AI model is helping researchers explore protein dynamics with increased speed. The deep learning system, called BioEmu, predicts the full range of conformations a protein ...

Replacing defective microglia can halt ALSP—a fatal neurodegenerative disease—in mice and humans, offering hope for broader brain therapies.

The designed proteins block hemoglobin from binding ChuA, an outer membrane bacterial protein, helping to inhibit E. coli's growth.

Mouse livers were engineered via a one-time genome editing to secrete a GLP-1, cutting weight gain and improving glucose ...

Pharmaceutical manufacturers are under immense pressure to streamline their processes, reduce waste, and improve output.

Merck & Co. has agreed to acquire Verona Pharma for $10 billion, the companies said, in a deal designed to expand the pharma ...

GREmLN leverages a graph-based architecture to represent gene-gene interactions to predict cell behavior for therapeutic ...

Revolution Medicines' proprietary data will train a bespoke version of NeuralPLexer, an AI model for protein-ligand ...

Methylation changes in microbiome-derived cfRNA enable more accurate CRC diagnosis than traditional DNA or abundance-based ...